Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Avadel Pharmaceuticals","sponsor":"Exela Pharma Sciences, LLC.","pharmaFlowCategory":"D","amount":"$42.0 million","upfrontCash":"$14.5 million","newsHeadline":"Avadel Sells Sterile Injectables Portfolio; will Focus on Narcolepsy","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Musculoskeletal","graph2":"Approved"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Launches PREVDUO (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Small molecule","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Neostigmine Methyl Sulfate

    Menu

    Neostigmine Methyl Sulfate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Endo International

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Launches PREVDUO (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

              Details:

              PREVDUO (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine–glycopyrrolate combination product in the U.S for Neuromuscular blockade.

              Lead Product(s): Neostigmine Methylsulfate,Glycopyrronium Bromide

              Therapeutic Area: Neurology Product Name: Prevduo

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Avadel Pharmaceuticals

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Avadel Sells Sterile Injectables Portfolio; will Focus on Narcolepsy

              Details:

              Company announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™ o Exela Sterile Medicines LLC.

              Lead Product(s): Neostigmine Methylsulfate

              Therapeutic Area: Musculoskeletal Product Name: Bloxiverz

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Exela Pharma Sciences, LLC.

              Deal Size: $42.0 million Upfront Cash: $14.5 million

              Deal Type: Divestment July 01, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY